CUL4A抗体—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane 1-4: HepG2, Hela, 231 cell and Human fetal brain tissue lysates, Primary antibody: P10783(CUL4A Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P10783(CUL4A Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10783(CUL4A Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

The CUL4A antibody is a research tool targeting Cullin 4A (CUL4A), a core component of the Cullin-RING E3 ubiquitin ligase complex (CRL4). CUL4A functions as a scaffold protein, assembling with adaptors like DDB1. substrate receptors (e.g., DCAFs), and the RING protein ROC1/RBX1 to mediate substrate-specific ubiquitination. This post-translational modification typically marks proteins for proteasomal degradation or functional modulation. CUL4A plays critical roles in DNA damage repair, cell cycle regulation, chromatin remodeling, and genomic stability by targeting substrates such as p21. p53. CDT1. and histone H2B. Dysregulation of CUL4A is implicated in cancers (e.g., hepatocellular carcinoma, breast cancer) and developmental disorders.

CUL4A antibodies are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to detect protein expression, localization, and interaction partners. They help elucidate CUL4A's involvement in disease mechanisms and its crosstalk with signaling pathways. Commercial CUL4A antibodies are typically validated for specificity against human CUL4A isoforms, though cross-reactivity with CUL4B (a paralog sharing ~80% homology) must be considered. Research using these antibodies has revealed CUL4A's oncogenic potential through overexpression in tumors and its role in chemoresistance, making it a potential therapeutic target. Proper validation via knockout/knockdown controls is essential to ensure antibody reliability in experimental settings.